The Clinical Research Group of the Department of Microbiology, Immunology and Tropical Medicine (MITM-CRG) is part of the Research Center for Neglected Diseases of Poverty, located at the George Washington University School of Medicine and Health Sciences. The MITM-CRG is part of the Texas Children's Hospital Center for Vaccine Development - Product Development Partnership (PDP) and conducts clinical research trials of experimental products that are being developed for the prevention of neglected tropical diseases, particularly hookworm infection and schistosomiasis.
We are working to develop and test a novel, low-cost hookworm vaccine to help control human hookworm infection in endemic countries. Hookworm infection causes anemia and can lead to problems with physical and cognitive development in children (see Research Interests).
We are currently conducting first-in-human studies of two hookworm vaccine candidates, Na-GST-1 and Na-APR-1 (see Clinical Trials). Additionally, we are developing a controlled experimental infection model for hookworm. In this model, we will immunize healthy volunteers with our candidate vaccine and we will then give them an effective dose of hookworm larvae, which is transmitted through skin penetration, to test for the protective effect of the vaccine.
Clinical Trials Capabilities
The MITM-CRG is located at the GW School of Medicine and Health Sciences, within state-of-the-art facilities of the Research Center for Neglected Diseases of Poverty, which opened in November 2013.
The MITM-CRG is committed to providing a full range of research services to facilitate the development, implementation, and successful completion of clinical trials. The CRG ensures compliance with federal, state, and institutional regulations, policies, and procedures to protect the interests of study participants.
The MITM-CRG consists of clinical investigators, with specialty board certification and faculty appointments at the George Washington University, a physician assistant and research coordinators. As a group we have combined experience in translational, Phase I, II, III, and IV clinical trials, and epidemiological studies.